Stock Track | Insmed Plummets 15.98% Intraday as Arikayce Sales Miss Expectations and Policy Concerns Weigh

Stock Track05-07 23:28

Insmed's stock experienced a sharp intraday plummet of 15.98% on Thursday, reflecting significant investor concern following the release of the company's first-quarter financial results.

The decline was primarily driven by the company's key lung disease treatment, Arikayce, missing first-quarter sales expectations. Arikayce generated revenue of $98.1 million, falling short of the average analyst expectation of $105.4 million. Furthermore, the company indicated that evolving U.S. policies are being evaluated for their potential impact on the international launch timing for its other lung disease treatment, Brinsupri, adding to market uncertainty.

While Insmed reported a narrower quarterly loss per share of $0.76 compared to an expected loss of $0.96, and total revenue of $306 million beat estimates, the market reaction highlighted investor focus on the sales miss for a core product and concerns over the company's ongoing substantial net losses, which totaled $163.6 million for the quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1108965084?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 23:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1108965084","market":"nz","top_or_hot":-1,"title":"Stock Track | Insmed Plummets 15.98% Intraday as Arikayce Sales Miss Expectations and Policy Concerns Weigh","media":"Stock Track","content":"<p>Insmed's stock experienced a sharp intraday plummet of 15.98% on Thursday, reflecting significant investor concern following the release of the company's first-quarter financial results.</p><p>The decline was primarily driven by the company's key lung disease treatment, Arikayce, missing first-quarter sales expectations. Arikayce generated revenue of $98.1 million, falling short of the average analyst expectation of $105.4 million. Furthermore, the company indicated that evolving U.S. policies are being evaluated for their potential impact on the international launch timing for its other lung disease treatment, Brinsupri, adding to market uncertainty.</p><p>While Insmed reported a narrower quarterly loss per share of $0.76 compared to an expected loss of $0.96, and total revenue of $306 million beat estimates, the market reaction highlighted investor focus on the sales miss for a core product and concerns over the company's ongoing substantial net losses, which totaled $163.6 million for the quarter.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Insmed Plummets 15.98% Intraday as Arikayce Sales Miss Expectations and Policy Concerns Weigh</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Insmed Plummets 15.98% Intraday as Arikayce Sales Miss Expectations and Policy Concerns Weigh\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-07 23:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Insmed's stock experienced a sharp intraday plummet of 15.98% on Thursday, reflecting significant investor concern following the release of the company's first-quarter financial results.</p><p>The decline was primarily driven by the company's key lung disease treatment, Arikayce, missing first-quarter sales expectations. Arikayce generated revenue of $98.1 million, falling short of the average analyst expectation of $105.4 million. Furthermore, the company indicated that evolving U.S. policies are being evaluated for their potential impact on the international launch timing for its other lung disease treatment, Brinsupri, adding to market uncertainty.</p><p>While Insmed reported a narrower quarterly loss per share of $0.76 compared to an expected loss of $0.96, and total revenue of $306 million beat estimates, the market reaction highlighted investor focus on the sales miss for a core product and concerns over the company's ongoing substantial net losses, which totaled $163.6 million for the quarter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INSM","symbol_name":"Insmed","start_time":0,"source_url":"","article_id":"1108965084","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1108965084","pubTimestamp":1778167699,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Insmed's stock experienced a sharp intraday plummet of 15.98% on Thursday, reflecting significant investor concern following the release of the company's first-quarter financial results.The decline...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INSM":"Insmed"},"translate_title":"个股追踪|Insmed盘中暴跌15.98%，因Arikayce销售不及预期且政策担忧承压","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INSM":1},"content_text":"Insmed's stock experienced a sharp intraday plummet of 15.98% on Thursday, reflecting significant investor concern following the release of the company's first-quarter financial results.The decline was primarily driven by the company's key lung disease treatment, Arikayce, missing first-quarter sales expectations. Arikayce generated revenue of $98.1 million, falling short of the average analyst expectation of $105.4 million. Furthermore, the company indicated that evolving U.S. policies are being evaluated for their potential impact on the international launch timing for its other lung disease treatment, Brinsupri, adding to market uncertainty.While Insmed reported a narrower quarterly loss per share of $0.76 compared to an expected loss of $0.96, and total revenue of $306 million beat estimates, the market reaction highlighted investor focus on the sales miss for a core product and concerns over the company's ongoing substantial net losses, which totaled $163.6 million for the quarter.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1108965084","isCrawlerRequest":true}